Supernus Pharmaceuticals (SUPN) Free Cash Flow (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Free Cash Flow of -$5.4 million for Q2 2026, down 109.26% year-over-year from $58.1 million in Q2 2025, and down 108.08% on a QoQ basis from $66.5 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Free Cash Flow (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Free Cash Flow for 16 years, with the latest figure at -$5.4 million in Q2 2026.
- Free Cash Flow for Q2 2026 came in at -$5.4 million, down 109.26% year-over-year; the trailing twelve-month figure through Jun 2026 was $18.8 million (down 89.89% YoY), and the FY2025 annual result was $46.0 million, down 73.14% from the prior year.
- Free Cash Flow retreated to -$5.4 million in Q2 2026, from $66.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $71.4 million in Q2 2022 and troughed at -$61.8 million in Q3 2025.
- A 5-year average of $28.1 million and a median of $35.6 million in 2023 frame the typical range for Free Cash Flow.
- The widest annual swing landed in 2023, when Free Cash Flow jumped 1315.47%; it then sank 215.89% in 2025.
- A 5-year view of Free Cash Flow shows it stood at $27.7 million in 2022, then soared by 62.25% to $45.0 million in 2023, then dropped by 1.78% to $44.2 million in 2024, then slumped by 56.02% to $19.4 million in 2025, then slumped by 127.67% to -$5.4 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were -$5.4 million in Q2 2026, $66.5 million in Q1 2026, and $19.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | -5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.38 Mn |
| Jun 30, 2026 | -5.38 Mn |
| Mar 31, 2026 | 66.52 Mn |
| Mar 31, 2026 | 66.52 Mn |
| Dec 31, 2025 | 19.43 Mn |
| Dec 31, 2025 | 19.43 Mn |
| Sep 30, 2025 | -61.79 Mn |
| Sep 30, 2025 | -61.79 Mn |
| Jun 30, 2025 | 58.08 Mn |
| Jun 30, 2025 | 58.08 Mn |
| Mar 31, 2025 | 30.27 Mn |
| Mar 31, 2025 | 30.27 Mn |
| Dec 31, 2024 | 44.19 Mn |
| Dec 31, 2024 | 44.19 Mn |
| Sep 30, 2024 | 53.32 Mn |
| Sep 30, 2024 | 53.32 Mn |
| Jun 30, 2024 | 35.56 Mn |
| Jun 30, 2024 | 35.56 Mn |
| Mar 31, 2024 | 38.15 Mn |
| Mar 31, 2024 | 38.15 Mn |